The association between CDH1 promoter methylation and patients with ovarian cancer: a systematic meta-analysis

Qiang Wang¹, Bing Wang², Yun-mei Zhang³ and Wei Wang⁴*

Abstract

Background: The down-regulation of E-cadherin gene (CDH1) expression has been regarded as an important event in cancer invasion and metastasis. However, the association between CDH1 promoter methylation and ovarian cancer remains unclear. A meta-analysis was conducted to evaluate the potential role of CDH1 promoter methylation in ovarian cancer.

Methods: Relevant articles were identified by searches of PubMed, EMBASE, Cochrane Library, CNKI and Wanfang databases. The pooled odds ratio (OR) and corresponding 95% confidence interval (CI) were calculated to assess the strength of association.

Results: Nine studies were performed using the fixed-effects model in this study, including 485 cancer tissues and 255 nonmalignant tissues. The findings showed that CDH1 promoter methylation had an increased risk of ovarian cancer in cancer tissues (OR = 8.71, P < 0.001) in comparison with nonmalignant tissues. Subgroup analysis of the ethnicity showed that the OR value of CDH1 methylation in Asian population subgroup (OR = 13.20, P < 0.001) was higher than that in Caucasian population subgroup (OR = 3.84, P = 0.005). No significant association was found between ovarian cancer and low malignant potential (LMP) tumor (P = 0.096) among 2 studies, and between CDH1 promoter methylation and tumor stage and tumor histology (all P > 0.05). There was not any evidence of publication bias by Egger’s test (all P > 0.05).

Conclusions: CDH1 promoter methylation can be a potential biomarker in ovarian cancer risk prediction, especially Asians can be more susceptible to CDH1 methylation. However, more studies are still done in the future.

Keywords: CDH1 promoter, Methylation, Ovarian cancer, LMP

Background

Ovarian cancer, the most lethal tumor in gynecologic cancers, is the fifth most cause of cancer-related deaths among women. According to cancer statistics, approximately 21,290 women will be diagnosed and 14,180 will die due to ovarian cancer in the United States in 2015 [1]. Among ovarian cancer, serous ovarian carcinoma is the most common histotype and only less than 20% of ovarian cancer can be detected early due to the lack of effective early detection and accurate diagnosis methods [2]. More than 80% of ovarian cancer patients at advanced stages relapse [3]. While the overall 5-year survival rate is only 31% [4].

Epigenetic alterations (DNA methylation, histone modifications, nucleosome positioning and non-coding RNAs) are identified to be strongly associated with cancer [5]. DNA methylation is an important mechanism of epigenetic variability involved in gene expression, which plays key roles in the development of cancer [6–8]. Aberrant methylation of CpG islands of the promoter regions is the major alternative to accomplish tumor suppressor gene (TSG) silencing [9–11]. CDH1, a tumor suppressor gene, also called as epithelial cadherin (E-cadherin) and cadherin-1, is located on 16q23 [12]. CDH1, a member of the cadherin family, plays an important role in epithelial cell-cell adhesion and in maintaining normal tissue architecture [13].
The reduction of CDH1 expression may involve in invasion and metastasis of several cancers [13–15].

However, the association between CDH1 promoter methylation and ovarian cancer remains to be certified. In this study, we performed a meta-analysis to evaluate the relationships between ovarian cancer tissues and nonmalignant ovarian tissues and Low malignant potential (LMP) tumor tissues. In addition, we also assess the relationship between CDH1 promoter methylation and clinicopathological features in ovarian cancer.

Methods

Literature search and selection criteria

A systematic literature search was performed in PubMed, EMBASE, Cochrane Library, CNKI and Wanfang databases, using the following keywords and search items: (CDH1 OR E-cadherin OR cadherin 1) AND (ovarian OR ovary) AND (cancer OR carcinoma OR tumor) AND methylation. The search updated until December 25. 2015. Moreover, a manual search of the references was also conducted to identify the potentially additional articles.

For eligible studies, studies must meet the following criteria: (1) all patients were diagnosed for primary ovarian cancer; (2) the study was about CDH1 promoter methylation and ovarian cancer; (3) study must have sufficient data about the frequencies of CDH1 promoter methylation to assess to the relationship between CDH1 promoter methylation and ovarian cancer; (4) only the most recent paper or the most complete one was selected to avoid duplicated publications. Study was excluded if it did not meet the inclusion criteria above.

Data extraction

For each eligible study, the following information were extracted: the first author’s name, publication year, methylation region, country, ethnicity, the method of methylation detection, type of control, the number of methylation, the sample size, clinicopathological parameters, such as the number of tumor stage, the number of tumor histology, etc. Nonmalignant ovarian tissues were defined as controls, including benign disease, normal tissues or adjacent normal tissues. Low malignant potential (LMP) tumors were also served as a single control group.

Statistical analysis

Meta-analysis was conducted using the STATA software (version 12.0, Stata Corporation, College Station, TX, USA). The pooled odds ratios (OR) and 95% confidence interval (95% CI) were calculated to evaluate the association between CDH1 promoter methylation and ovarian cancer risk. Between-study heterogeneity was examined using the Cochran’s Q test and I² statistic [16]. If I² < 50% and p ≥ 0.1 were considered as a measure of lack heterogeneity, a fixed-effects model was applied; otherwise, the random-effects model was used [17, 18]. Publication bias was assessed by using Egger’s linear regression test [19].

Results

Study characteristics

One hundred twenty-seven potentially relevant articles were initially identified by the databases above. These studies were further selected based on the inclusion criteria. Finally, a total of 9 studies met the inclusion criteria were included in the current meta-analysis (Fig. 1). The methylation region of these studies was promoter. Among these studies, 8 studies used methylation-specific polymerase chain reaction (MSP) and 1 study used methylation specific headloop suppression PCR (MSHSP). There were two control groups, including nonmalignant control with 8 studies and LMP control with 2 studies. 8 studies evaluated the association between CDH1 promoter methylation and ovarian cancer risk, 4 studies evaluated the relationship between CDH1 and tumor histology, and 3 studies assessed the relationship between CDH1 and tumor stage. The main characteristics of included studies were listed in Table 1 [20–26].

The association between CDH1 promoter methylation and OC risk

Significant between-study heterogeneity was not detected (I² = 16.6% and P = 0.299), a fixed-effects model was used. A significant association was observed between CDH1 promoter methylation and ovarian cancer among 8 studies (OR = 8.71, 95% CI = 4.87 – 15.58, P < 0.001), including 435 malignant tissues from ovarian cancer and 255 nonmalignant tissues (Fig. 2). Subgroup analysis based on the ethnic population showed that the CDH1 promoter methylation status was significant associated with the risk of ovarian cancer in Asian population and Caucasian population (OR = 13.20, 95% CI = 6.12 – 28.45, P < 0.001; OR = 3.84, 95% CI = 1.52 – 9.74, P = 0.005; respectively) (Fig. 3). No significant association was found in the comparison of ovarian cancer and LMP tumor (OR = 2.40, 95% CI = 0.86 – 6.76, P = 0.096), reporting a total of 109 ovarian cancer patients and 37 low malignant tumor patients in 2 studies (Table 2).

The association of CDH1 promoter methylation and clinicopathological features

The associations between CDH1 promoter methylation and clinicopathological features were further analyzed in the present meta-analysis (Table 2), such as tumor stage (57 early ovarian cancer patients vs. 142 advanced ovarian cancer patients) and tumor histology (122 serous cancer patients vs. 82 non-serous cancer patients), including 3 studies and 4 studies respectively. Between-study heterogeneity was lack (P > 0.1), the fixed-effects model was used. The result showed that CDH1 promoter methylation
Table 1 The main characteristics of included studies in this meta-analysis

| First author          | Region | Country   | Race       | Method | Sample | Control | Case   | Control | Stage 1-2 | Stage 3-4 | Serous | Non-serous |
|-----------------------|--------|-----------|------------|--------|--------|---------|--------|---------|-----------|-----------|--------|------------|
| Rathi 2002 [35]      | Promoter | USA       | Caucasians | MSP    | Tissue | NMT     | 14/49  | 2/39    | -         | -         | -      | -          |
| Makarla 2005 [21]    | Promoter | USA       | Caucasians | MSP    | Tissue | NMT     | 6/23   | 4/39    | -         | -         | 2/9    | 3/13       |
| Makarla 2005 [21]    | Promoter | USA       | Caucasians | MSP    | Tissue | LMP     | 6/23   | 4/23    | -         | -         | -      | -          |
| Yuecheng 2006 [26]   | Promoter | China     | Asians     | MSP    | Tissue | NMT     | 34/80  | 0/34    | -         | -         | -      | -          |
| Shen 2007 [23]       | Promoter | China     | Asians     | MSP    | Tissue | NMT     | 18/63  | 1/30    | 2/22      | 16/41     | 9/34   | 9/29       |
| Montavon 2012 [34]   | Promoter | Australia | Caucasians | MSHSP  | Tissue | NMT     | 17/78  | 1/5     | -         | -         | -      | -          |
| Bhagat 2013 [20]     | Promoter | India     | Asians     | MSP    | Tissue | NM      | 31/86  | 2/34    | 8/23      | 23/63     | 17/44  | 7/25       |
| Bhagat 2013 [20]     | Promoter | India     | Asians     | MSP    | Tissue | LMP     | 31/86  | 2/14    | -         | -         | -      | -          |
| Wu 2014 [25]         | Promoter | China     | Asians     | MSP    | Tissue | NMT     | 32/50  | -       | 7/12      | 25/38     | 25/35  | 7/15       |
| Moselhy 2015 [22]    | Promoter | Saudi Arabia | Asians | MSP    | Tissue | NMT     | 12/18  | 8/32    | -         | -         | -      | -          |
| Sun and Zhang 2015 [24] | Promoter | China     | Asians     | MSP    | Tissue | NMT     | 15/38  | 1/42    | -         | -         | -      | -          |

MSP Methylation Specific PCR, MSHSP Methylation specific headloop suppression PCR, NMT nonmalignant tissues, LMP low malignant potential tumor, "-" indicates data not available, M stands for the number of methylation positive, N stands for the number of the total samples.
was not significantly associated with tumor histology and tumor stage (OR = 1.41, 95% CI = 0.76 - 2.60, P = 0.273; OR = 0.55, 95% CI = 0.28 - 1.08, P = 0.082; respectively).

Publication bias
Egger’s test was performed to estimate the publication bias of included studies. Egger’s test of CDH1 methylation of cancer versus nonmalignant control showed that there was not any evidence of publication bias (P = 0.335). No publication bias was detected in tumor histology and tumor stage (P = 0.935 and P = 0.316 respectively) (Table 2).

Discussion
The gene epigenomic regulation of initiation and progression of cancer has two essential components of the molecular mechanism, which are the hypermethylation of tumor suppressor genes and hypomethylation of oncogenes [27–29]. The CpG islands methylation of the promoter is an important reason for loss of gene expression, which can lead to the transcription repression of the gene [30]. Inactivation of CDH1 by promoter hypermethylation has been observed in several types of cancers, including breast cancer, ovarian cancer and gastric cancer [31–33]. However, the frequency of CDH1 promoter methylation was inconsistent. Montavon et al. reported that the frequency of CDH1 promoter methylation was 21.8% and 20% in ovarian cancer and nonmalignant ovarian disease respectively [34]. Rathi et al. reported that the frequency of CDH1 promoter methylation was 28.6% and 5% in ovarian cancer tissues and nonmalignant tissues respectively [35]. So the current meta-analysis was performed to identify the association between CDH1 promoter methylation and ovarian cancer risk.

A total of 9 studies including 485 cancer tissues and 255 nonmalignant tissues were involved in our study. CDH1 promoter methylation had an increased risk in cancer tissues (OR = 8.71, 95% CI = 4.87 - 15.58, P < 0.001) in comparison with nonmalignant tissues. Subgroup analysis based on the ethnicity suggested that the CDH1 promoter methylation status was significantly increased risks of ovarian cancer in Asian population and Caucasian population (OR = 13.20, 95% CI = 6.12 - 28.45; OR = 3.84, 95% CI = 1.52 - 9.74; respectively). The OR value of Asian population subgroup (OR = 13.20) was higher than that in Caucasian population subgroup (OR = 3.84), suggesting that Asian population can be more susceptible to
Fig. 3  Forest plot of the association between CDH1 promoter methylation and ovarian cancer based on subgroup analysis of the ethnicity

Table 2  Summary of the association of CDH1 promoter methylation and ovarian cancer

| Study ID | Overall OR 95% Cl | I²; p | P value | Cases | Controls | p (Egger's test) |
|----------|------------------|-------|---------|-------|----------|-----------------|
| NMT group | 8 | 8.71 (4.87 - 15.58) | 16.6%; 0.299 | <0.001 | 435 | 255 | 0.335 |
| Race | | | | | | | |
| Asians | 5 | 13.20 (6.12 - 28.45) | 0.0%; 0.545 | <0.001 | 285 | 172 | 0.884 |
| Caucasians | 3 | 3.84 (1.52 - 9.74) | 0.0%; 0.380 | 0.005 | 150 | 83 | 0.005 |
| LMP group | 2 | 2.40 (0.86 - 6.76) | 0.0%; 0.512 | 0.096 | 109 | 37 | 0.128 |
| Clinicopathological features | | | | | | | |
| Histology | | | | | | | |
| Patients | 4 | 1.41 (0.76 - 2.60) | 0.0%; 0.483 | 0.273 | 122 | 82 | 0.935 |
| Stage | | | | | | | |
| Patients | 3 | 0.55 (0.28 - 1.08) | 45.3%; 0.161 | 0.082 | 57 | 142 | 0.316 |

NMT nonmalignant tissues, LMP low malignant potential tumor
CDH1 promoter methylation. However, the results should be interpreted with caution as only small subjects were included in subgroup analyses. No significant association was observed between ovarian cancer and LMP tumor \((P = 0.096)\), including a total of 109 ovarian cancer patients and 37 low malignant tumor patients.

We further evaluated the relationships of CDH1 promoter methylation with clinicopathological features, such as tumor histology and tumor stage. Our findings indicated that the CDH1 promoter methylation status was not significantly associated with tumor stage and histology. Publication bias was not detected by Egger's test \((P > 0.05)\).

The current study had some limitations. Firstly, the search strategy was restricted to articles published in English or Chinese. Secondly, the total sample size was not sufficient larger \((\text{less than 1000)}\) \([36]\), our results may be lack vigorous power to evaluate the associations between CDH1 promoter methylation and ovarian cancer risk. Thirdly, based on the limitation of insufficient data, we did not study the CDH1 promoter methylation status in other clinicopathological features, such as tumor grade, sex status and age etc. Therefore, a meta-analysis including more studies with larger sample size should be necessary to confirm the results in the future.

Conclusion

CDH1 promoter methylation is significantly associated with ovarian cancer risk. In addition, the potential association on CDH1 promoter methylation and some clinicopathological features are still unclear due to the limitation of studies and sample size.

Ethics approval and consent to participate

Not applicable

Consent for publication

Not applicable.

Availability of data and material

All data is available in this paper.

Competing interests

The authors declare that they have no competing interests.

Authors' contributions

WW and QW contributed to the conception and design. QW, BW, YMZ, and WW contributed to completion of articles, the data extraction, data calculated and design of figures and tables. All the authors approved the final manuscript.

Funding

None.

Author details

1. Obstetrics and Gynecology Department, The Second Hospital of Jilin University, Changchun 130041, China. 2. Plastic Surgery Department, China-Japan Friendship Hospital Affiliated Jilin University, Changchun 130033, China. 3. Obstetrics and Gynecology Department, The Second People's Hospital of Dunhua, Dunhua 133700, China. 4. Radiology Department, The First Hospital of Jilin University, Changchun 130041, China.

Received: 21 February 2016 Accepted: 23 March 2016

Published online: 11 April 2016

References

1. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.
2. Kaja S et al. Detection of novel biomarkers for ovarian cancer with an optical nanotechnology detection system enabling label-free diagnostics. J Biomed Opt. 2012;17(8):081412–8.
3. Hall M et al. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer. 2013;108(2):250–8.
4. Network CGAR. Integrated genomic analyses of ovarian carcinoma. Nature. 2011;474(7353):609–15.
5. Khan SA, Reddy D, Gupta S. Global histone post-translational modifications and cancer: Biomarkers for diagnosis, prognosis and treatment? World J Biol Chem. 2015;6(4):333–45.
6. Poulovt M-C et al. The role of methylation in breast cancer susceptibility and treatment. Anticancer Res. 2015;35(9):4569–74.
7. Carrió E, Suelves M. DNA methylation dynamics in muscle development and disease. Front Aging Neurosci. 2015;7:19.
8. Henning SM et al. Epigenetic effects of green tea polyphenols in cancer. Epigenomics. 2013;5(6):729–41.
9. Herman JG, Baylin SB. Gene silencing in cancer in association with promoter hypermethylation. N Engl J Med. 2000;342(11):1069–81.
10. Esteller M, Herman JG. Cancer as an epigenetic disease: DNA methylation and chromatin alterations in human tumours. J Pathol. 2002;196(1):7–7.
11. Huang T et al. Meta-analyses of gene methylation and smoking behavior in non-small cell lung cancer patients. Sci Rep. 2015;5:8897.
12. Berx G et al. E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J. 1995;14(24):6107–15.
13. Oka H et al. Expression of E-cadherin cell adhesion molecules in human breast cancer tissues and its relationship to metastasis. Cancer Res. 1993;53(7):1696–701.
14. Takeuchi M. Cadherin cell adhesion receptors as a morphogenetic regulator. Science. 1991;251(5000):1451–5.
15. Tkanou E et al. The E-cadherin adhesion molecule and colorectal cancer. A global literature approach. Anticancer Res. 2008;28(6A):3815–26.
16. Coory MD. Comment on: Heterogeneity in meta-analysis should be expected and appropriately quantified. Int J Epidemiol. 2010;39(3):932.
17. Higgins JP et al. Measuring inconsistency in meta-analyses. BMJ. 2003;327(7414):557.
18. DerSimonian R. Meta-analysis in the design and monitoring of clinical trials. Stat Med. 1996;15(12):1237–54.
19. Peters JL et al. Comparison of two methods to detect publication bias in meta-analysis. JAMA. 2006;295(6):676–80.
20. Bhagat R et al. Altered expression of β-catenin, E-cadherin, and E-cadherin promoter methylation in epithelial ovarian carcinoma. Tumor Biol. 2013;34(4):2459–68.
21. Nakarla PB et al. Promoter hypermethylation profile of ovarian epithelial neoplasms. Clin Cancer Res. 2005;11(5):15365–9.
22. Moselhy SS et al. Hypermethylation of P15, P16, and E-cadherin genes in ovarian cancer. Toxicol Ind Health. 2011;27(10):924–30.
23. Shen WJ et al. Promoter hypermethylation of CDH1 gene in epithelial ovarian carcinoma. Chin J Pract Gynecol Obstet. 2007;23(07):520–2.
24. Sun B, Zhang X. Value of abnormal methylation of CDH1 gene and the detection of serum HE4 in the identification of ovarian cancer and ovarian endometriosis cyst. Hainan Med J. 2015;26(20):3023–5.
25. Wu X et al. Clinical importance and therapeutic implication of E-cadherin gene methylation in human ovarian cancer. Med Oncol. 2014;31(8):1–8.
26. Yuecheng Y, Hongmei L, Xiaoyan X. Clinical evaluation of E-cadherin expression and its regulation mechanism in epithelial ovarian cancer. Clin Exp Metastasis. 2006;23(1):65–74.
27. Bodmer W. 1998 Runrne Shaw Memorial Lecture; somatic evolution of cancer. Ann Acad Med Singapore. 1999;28(3):323–9.
28. Corson TW, Galle BL. One hit, two hits, three hits, more? Genomic changes in the development of retinoblastoma. Genes Chromosomes Cancer. 2007;46(7):177–34.
29. Franco R et al. Oxidative stress, DNA methylation and carcinogenesis. Cancer Lett. 2008;266(1):6–11.
30. Yoshiura K et al. Silencing of the E-cadherin invasion-suppressor gene by CpG methylation in human carcinomas. Proc Natl Acad Sci. 1995;92(16):7416–9.
31. Tamura G et al. E-Cadherin gene promoter hypermethylation in primary human gastric carcinomas. J Natl Cancer Inst. 2000;92(7):569–73.
32. Fearon ER. BRCA1 and E-Cadherin promoter hypermethylation and gene inactivation in cancer—association or mechanism? J Natl Cancer Inst. 2000;92(7):515–7.
33. Liu X, Chu K-M. E-cadherin and gastric cancer: cause, consequence, and applications. Biomed Res Int. 2014;2014:637508.
34. Montavon C et al. Prognostic and diagnostic significance of DNA methylation patterns in high grade serous ovarian cancer. Gynecol Oncol. 2012;124(3):582–8.
35. Rathi A et al. Methylation profiles of sporadic ovarian tumors and nonmalignant ovaries from high-risk women. Clin Cancer Res. 2002;8(11):3324–31.
36. Karahalios A et al. A review of the reporting and handling of missing data in cohort studies with repeated assessment of exposure measures. BMC Med Res Methodol. 2012;12(1):56.